IPCALAB vs MANGALAM: Stock Comparison

IPCA Laboratories Limited vs Mangalam Drugs And Organics Limited

Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings

IPCA Laboratories Limited is the larger company by market capitalisation. IPCA Laboratories Limited shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of IPCA Laboratories Limited and Mangalam Drugs And Organics Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, IPCALAB is more favourable on 11 of 11 scored metrics and MANGALAM on 0These counts are context-free and are not an overall rating.

Key Differences

Market Cap
IPCALAB is the larger company
₹45,033 Cr vs ₹43 Cr
EPS
IPCALAB has higher earnings per share
₹45.05 vs ₹-28.05
Dividend Yield
IPCALAB has a higher dividend yield
0.33% vs 0%
Revenue Growth (TTM YoY)
IPCALAB has faster revenue growth
6.2% vs -7.5%
EPS Growth (TTM YoY)
IPCALAB has faster EPS growth
341.6% vs 0%
Qtr Sales Growth
IPCALAB has stronger quarterly sales growth
6.31% vs -7.54%
Qtr Profit Growth
IPCALAB has stronger quarterly profit growth
80.9% vs -22,467%
ROE
IPCALAB has a higher ROE
16% vs -35.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricIPCALABMANGALAM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricIPCALABMANGALAM
Live Price₹1,779.1₹27.08
Day Change-1.11%-0.66%
Volume1.64 L25,356
52-Week High₹1,944.9₹95
52-Week Low₹1,251.6₹22.8
Distance from 52W High-8.52%-71.49%

Valuation

MetricIPCALABMANGALAM
Market Cap₹45,033 Cr₹43 Cr
P/E Ratio39.94x
P/B Ratio5.65x
EPS₹45.05₹-28.05
Book Value₹317.84₹65.12
Dividend Yield0.33%0%

Growth

MetricIPCALABMANGALAM
Revenue Growth (TTM YoY)6.2%-7.5%
EPS Growth (TTM YoY)341.6%0%
Qtr Sales Growth6.31%-7.54%
Qtr Profit Growth80.9%-22,467%

Profitability & Leverage

MetricIPCALABMANGALAM
ROE16%-35.2%
ROCE17.3%-14.3%
Net Margin11.83%-19.13%
Operating Margin20.5%-6.42%
Debt to Equity0.1x1.02x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricIPCALABMANGALAM
Promoter Holding44.72%35.65%
FII Holding10.73% 0.1 pp0.11% 0.21 pp
DII Holding37.37% 0.08 pp0%
Public Holding7.18% 0.02 pp64.24% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: IPCA Laboratories Limited and Mangalam Drugs And Organics Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.